Age-Related Macular Degeneration & Complement Therapeutic Research Introduction

Q: What AMD and complement therapeutic research services does Creative Biolabs provide?

Creative Biolabs provides complement genetic and functional studies, factor H and factor I characterization, pathway and activation-product testing, C3 and C5b-9 deposition assays, retinal cell studies, endothelial assays, biomarker profiling, AMD model development, and complement-targeted candidate evaluation.

Q: Which complement biomarkers can be measured in AMD research samples?

Options include Ba or Bb, C3a, C5a, C3d, sC5b-9, C3, C4, factor B, factor D, factor H, factor I, pathway functional activity, C3-fragment deposition, and membrane attack complex deposition.

Q: What information is needed to design a customized AMD study?

Useful information includes the AMD stage or model, proposed complement target or genetic finding, available sample and species, retinal compartment, candidate format, concentration range, benchmark, biomarkers, phenotype endpoints, timeline, and the decision the study must support.

AMD Research Support

Connect Complement Dysregulation to the Retinal Outcome Your Program Must Explain or Modify

Integrated studies for mechanism discovery, target validation, and therapeutic decisions

Creative Biolabs supports AMD programs in which complement is a causal hypothesis, a patient-stratification variable, a pharmacodynamic pathway, or a therapeutic target. Projects can begin with a risk variant in CFH, CFI, C3, CFB, or the CFHR locus; a retinal model showing complement-dependent stress; an ocular or circulating biomarker set; or an antibody, protein, peptide, aptamer, small molecule, or gene-based candidate.

We help translate that starting point into a staged research plan that aligns the complement source, retinal compartment, disease phase, trigger, assay matrix, comparator, candidate exposure, and success criteria. Studies are suitable for early target discovery, functional genetics, dry AMD and geographic atrophy research, neovascular AMD mechanism studies, biomarker development, lead selection, and preclinical proof of concept.

Programs may combine complement genetic testing, complement function and activity assays, retinal cell models, deposition analysis, angiogenesis readouts, and candidate-response testing.

Mechanism Mapping

Locate the pathway, compartment, surface, and disease phase where control is lost.

Functional Genetics

Test whether AMD-associated variants alter expression, binding, cofactor activity, or C3 regulation.

Retinal Model Studies

Connect complement activity to RPE, photoreceptor, immune, endothelial, and tissue outcomes.

Therapeutic Evaluation

Rank candidates by target engagement, pathway correction, retinal protection, and selectivity.

Starting with an AMD phenotype rather than a defined complement target?

We can begin with pathway, activation-product, and deposition profiling before committing to a target-specific efficacy package.

Request an AMD Complement Study Plan

Mechanistic Framework

Resolve the Sequence from Susceptibility to Retinal Injury

AMD is heterogeneous: a complement risk allele does not define the complete phenotype, and pathway activation can be systemic, locally produced, surface restricted, or stress dependent. We therefore build experiments around a mechanistic chain that can be challenged at each step.

Susceptibility and Trigger

Complement risk or protective variants, aging, oxidative stress, lipid accumulation, smoking-related stress, extracellular matrix changes, or project-defined inflammatory triggers.

Loss of Local Regulation

Altered factor H or factor I activity, impaired surface recognition, increased alternative-pathway amplification, insufficient RPE protection, or changed complement production.

Deposits and Tissue Stress

C3 fragments, terminal-complex deposition, drusen-associated proteins, RPE dysfunction, inflammatory signaling, immune-cell recruitment, and photoreceptor vulnerability.

Advanced Phenotype

Geographic atrophy, outer-retinal degeneration, choroidal endothelial activation, vascular leakage, neovascular lesion growth, or treatment-modifiable biomarker patterns.

Questions we can test

Does the proposed variant change factor H or factor I function? Is systemic complement activity reflected in the retinal phenotype? Which complement product accumulates on RPE or matrix surfaces? Does a candidate preserve RPE viability without completely suppressing host-defense activity?

Mechanism controls

Wild-type and risk-variant proteins, complement-depleted and reconstituted serum, heat-inactivated serum, pathway-selective blockade, oxidative or lipid stress controls, anti-VEGF or complement benchmarks, and rescue with a functional regulator can be used to establish causality.

Explore Ophthalmology Complement Research Services

Integrated Assay Capabilities

Measure Pathway Activity and Retinal Consequence in One Experimental Story

Modules can be used independently or assembled into a staged package. Complement sources, serum concentration, stress exposure, time points, candidate dosing, and comparators are aligned so molecular and phenotypic results remain interpretable.

Genetic & Molecular

Variant and Protein Characterization

Determine whether an AMD-associated variant changes regulator abundance or quality.

Genotyping and targeted variant analysis
Expression, secretion, and stability
Wild-type and variant protein production
Domain and processing assessment

Interaction

Binding and Regulatory Function

Quantify the interactions that control alternative-pathway amplification on retinal surfaces.

C3b, factor H, factor I, and matrix binding
ELISA, competition, SPR, or BLI
Cofactor and decay-acceleration activity
C3b degradation and iC3b generation

Pathway

Complement Function and Activation Products

Measure the net effect of disease context or treatment across the cascade.

Classical, lectin, and alternative activity
C3a, C5a, Ba/Bb, C3d, and sC5b-9
Component consumption and reconstitution
Pathway-selective inhibition

Surface

Deposition and Cell Protection

Resolve whether complement accumulates on RPE, matrix, endothelial, or model surfaces.

C3b/iC3b and C4 fragment deposition
C5b-9 membrane deposition
Cell viability and complement-dependent injury
Barrier and surface-protection assays

Retinal Phenotype

RPE, Inflammation, and Angiogenesis

Connect pathway modulation to outputs relevant to atrophy or neovascular disease.

Oxidative stress and phagocytic function
Cytokines and inflammasome-related endpoints
Endothelial migration, tubes, and permeability
VEGF-associated and immune-cell responses

Translational

Biomarker and Integrated Data Analysis

Link genotype, pathway markers, retinal phenotype, and candidate response.

Serum, plasma, ocular fluid, and supernatant panels
Multiplex and orthogonal confirmation
Donor and matrix variability analysis
Pharmacodynamic marker selection

Need to distinguish pathway suppression from nonspecific retinal-cell toxicity?

Matched cell-health, heat-inactivated serum, depleted-serum, and reconstitution controls can be built into the same study.

Explore Complement Inhibitor Validation

Experimental Systems

Match Model Complexity to the AMD Question

Purified systems are useful for variant mechanism, whereas retinal protection and candidate efficacy require the appropriate cell surface, extracellular matrix, stressor, complement source, and disease endpoint. We advance models only after the preceding assay tier is qualified.

Purified and Reconstituted Complement

Wild-type and variant proteins, depleted and reconstituted sera, convertase components, modified surfaces, and defined matrices for direct molecular and pathway studies.

RPE and Photoreceptor Systems

ARPE-19, primary or donor-derived RPE, iPSC-derived RPE, photoreceptor-related cells, oxidative or lipid stress, barrier models, and complement-dependent injury.

Choroidal and Immune Co-cultures

Endothelial migration, tube formation, permeability, RPE–endothelial interfaces, macrophage or microglial components, and cytokine or VEGF-associated readouts.

Organoid, Explant, and Preclinical Models

Retinal organoids, tissue explants, drusen- or matrix-relevant systems, geographic atrophy concepts, laser-induced CNV, and model-specific pharmacodynamic endpoints.

Sample types

SerumPlasmaOcular fluidRPE cellsEndothelial cellsSupernatantDNA/RNATissue

Model qualification factors

Complement competence, species compatibility, serum concentration, RPE maturity and polarity, extracellular matrix, oxidative or lipid stress, donor genotype, collection and storage, freeze–thaw history, ex vivo complement activation, candidate exposure, and the dynamic range of the selected retinal endpoint.

Plan an AMD Model Feasibility Study

Therapeutic Translation

Evaluate Complement Candidates at the Target, Pathway, and Retinal Phenotype Levels

A candidate is advanced only when its effect can be attributed to a defined complement mechanism and connected to retinal protection or vascular control in the selected AMD context.

Regulator restoration

Factor H or factor I replacement, engineered regulators, surface-targeted control, or functional rescue of a risk variant.

Proximal pathway blockade

C3, factor B, factor D, properdin, convertase, amplification-loop, or deposition-focused intervention.

Terminal and receptor targeting

C5, C5a/C5aR, membrane attack complex, C3a/C3aR, inflammatory signaling, or tissue-injury modulation.

Combination concepts

Complement modulation with anti-VEGF, antioxidant, anti-inflammatory, neuroprotective, or project-defined standard-of-care comparators.

Decision gates and representative outputs

Antibodies, recombinant proteins, peptides, aptamers, small molecules, gene-silencing tools, editing concepts, and local-delivery strategies can be compared using a milestone-based design.

Target binding or engagement

Pathway-selective pharmacodynamics

C3 or C5b-9 deposition reduction

RPE viability and barrier rescue

Inflammatory mediator suppression

Endothelial or CNV-related response

Dose–response and therapeutic window

Candidate and biomarker ranking

Explore Complement Inhibitor Development

Study controls may include vehicle, inactive analog, isotype, heat-inactivated serum, depleted and reconstituted serum, pathway-selective benchmarks, cell-health controls, and anti-angiogenic comparators.

Need study reagents and the assay package used to validate them?

Complement antibodies, proteins, inhibitors, and serum or plasma products can support controls, reconstitution, and candidate screening.

Explore Complement Research Products

Related Research

Functional Genetics and Complement Biomarkers in AMD

These original studies illustrate how complement variants can be tested beyond in silico prediction and how circulating pathway markers can be integrated with AMD-associated genetic information.

Complement factor I domain structure and CFI variants analyzed in AMD and aHUS

AMD genetics / CFI / C3b degradation

Functional analysis identifies impaired activity among AMD-associated factor I variants

De Jong and colleagues expressed 11 rare CFI missense variants and quantified C3b degradation and iC3b generation. The study demonstrates how variants with apparently normal secretion can still produce a measurable loss of regulatory function.

View research via DOI
CC BY 4.0

Locations and structural context of rare N-terminal complement factor H variants analyzed in AMD, aHUS, and C3G

AMD genetics / CFH / functional characterization

Rare N-terminal factor H variants show distinct functional consequences

Wong and colleagues compared six CFH variants using C3b binding, surface plasmon resonance, cofactor assays, decay-acceleration studies, and hemolytic assays. Results separated a severe loss-of-function variant from subtler effects relevant to chronic complement-driven disease.

View research via DOI
CC BY 4.0

Alternative complement pathway proteins, activation markers, and AMD-associated polymorphic variants analyzed in a patient study

AMD cohort / systemic complement / biomarkers

Systemic complement activation correlates with AMD and complement genetics

Scholl and colleagues measured activation products and complement proteins in AMD patients and controls while analyzing CFH, BF-C2, and C3 genetic markers. Ba, C3d, factor D, and other activation products supported an integrated biomarker–genotype strategy.

View research via DOI
CC BY

Explore Complement Factor H Functional Testing

Questions and Answers

Frequently Asked Questions

What AMD and complement therapeutic research services does Creative Biolabs provide?

We provide complement genetic and functional studies, factor H and factor I characterization, pathway and activation-product testing, C3 and C5b-9 deposition assays, RPE and retinal cell studies, endothelial and angiogenesis assays, biomarker profiling, AMD model development, and complement-targeted candidate evaluation.

Can you study both geographic atrophy and neovascular AMD mechanisms?

Yes. Geographic atrophy-related programs can focus on chronic RPE or photoreceptor stress, complement deposition, inflammatory signaling, barrier function, and cell protection. Neovascular programs can add choroidal endothelial migration, tube formation, permeability, VEGF-associated signaling, macrophage responses, and lesion-related endpoints.

Can AMD-associated CFH or CFI variants be functionally evaluated?

Yes. Wild-type and variant proteins can be compared for expression, secretion, stability, C3b or surface binding, factor I cofactor activity, C3b degradation, decay acceleration, pathway output, deposition, and rescue. The exact panel depends on the affected domain and proposed mechanism.

Which complement biomarkers can be measured in AMD research samples?

Options include Ba/Bb, C3a, C5a, C3d, sC5b-9, C3, C4, factor B, factor D, factor H, factor I, pathway functional activity, C3-fragment deposition, and membrane attack complex deposition. The panel is selected according to sample type, disease question, and candidate mechanism.

Can you work with serum, plasma, ocular samples, or donor-derived retinal cells?

Yes, subject to sample suitability, availability, consent, and project requirements. Feasibility planning considers collection and processing, anticoagulant, storage, freeze–thaw history, ex vivo complement activation, matrix interference, donor genotype, cell maturity, sample volume, and the controls required for interpretation.

Can complement inhibitors be tested with anti-VEGF or other benchmark treatments?

Yes. Complement candidates can be evaluated alone or with anti-angiogenic, antioxidant, anti-inflammatory, neuroprotective, or project-defined comparators. Studies can distinguish target engagement, complement pharmacodynamics, retinal protection, vascular response, additivity, and nonspecific toxicity.

What information is needed to design a customized AMD study?

Please provide the AMD stage or model, proposed complement target or genetic finding, available sample and species, retinal compartment, candidate format and amount, preferred concentration range, benchmark, required biomarkers and phenotype endpoints, timeline, and the decision the study must support. Unknown items can be resolved in a feasibility phase.

Ask About an AMD Complement Research Project

Scientific Literature

References

De Jong, Sarah, et al. “Functional Analysis of Variants in Complement Factor I Identified in Age-Related Macular Degeneration and Atypical Hemolytic Uremic Syndrome.” Frontiers in Immunology, vol. 12, 2022, article 789897. https://doi.org/10.3389/fimmu.2021.789897
Wong, Edwin K. S., et al. “Functional Characterization of Rare Genetic Variants in the N-Terminus of Complement Factor H in aHUS, C3G, and AMD.” Frontiers in Immunology, vol. 11, 2021, article 602284. https://doi.org/10.3389/fimmu.2020.602284
Scholl, Hendrik P. N., et al. “Systemic Complement Activation in Age-Related Macular Degeneration.” PLOS ONE, vol. 3, no. 7, 2008, e2593. https://doi.org/10.1371/journal.pone.0002593